
From: Stephanie Bishop <stephaniebishop420@gmail.com>
Sent: Tuesday, April 25, 2017 11:04 AM
To: JMR Exhibits
Subject: Opposition to SB 1057-23

Sarah Duff hits every point so eloquently, I just copied her email. I agree with every point and sub point in this email. I am a registered Oregon Voter and OMMP Patient. SB

Madam Co-Chairs and Members of the Marijuana Regulation Committee,

I am writing in opposition to SB 1057-23. SB 1057-23 will:

1. Create a trap for OLCC producers.
 - a. Creating a complicated reimbursement scheme could cause the Producer to lose money trying to help patients and could unnecessarily tempt them to get reimbursed in the illicit market, or violate the rules to sell more to the legal market rather than to patients.
 - b. There is hardly a medical marijuana market. Many patients spend all the money can spend on marijuana by getting their card and rely on growers to pay the bill for their medicine. If the grower can not get reimbursed for their costs because there is too small of a medical market, then they will be faced with an impossible decision whether to comply with the rules and laws.
2. Increase cost of participation and complicated system of compliance leads to less participation.
 - a. Medical growers already pay a significant fee to be compliant. By adding Metrc costs and expensive scales, too many growers will not be able to participate.
 - b. Compliance firms like my own will benefit but the state will lose participants which hurts Oregon.
3. 75% of harvest is problematic.
 - a. In theory I want patients to get 100% of medical marijuana produced but because it takes substantial money to produce cannabis for low income patients, the 25% that they can sell to stores is not likely to cover the expenses, especially if there is ever a problem with a harvest.
 - b. We want to incentivize producers to grow for patients and if they can not make even a small amount of profit, they will not participate.
4. Trade shows should be able to give out samples and allow patients and adults 21 and over to try more benign forms of cannabis.
 - a. Topicals and medium to low dose THC tinctures or CBD tinctures are benign forms of cannabis that have very little to no psychoactive effects. Our industry feels discriminated against when festivals allow the sampling of alcohol but we can not use even the most benign forms of cannabis at a trade shows. I understand SB 307 may address this issue and should be passed.
 - b. Thank you for your attention to regulating our young industry and for helping make Oregon a model for other states and nations.

Sarah Duff
Duff Johnson Consulting
Policy Advisor to New Approach Oregon

--

Stephanie Bishop
(541) 731-5222 Cell Phone
[Stephanie Bishop on Facebook](#)
[Adamson and Ratta Blog](#)
[Adamson and Ratta YouTube](#)
[Stephanie Bishop on Twitter](#)
[Stephanie Bishop on Google + \(Personal\)](#)
[Stephanie Bishop on Google + \(Professional\)](#)
[Hempsters The Movie](#)